Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEIBA PROOF: Prophylaxis vs On-Demand in Hemophilia with Inhibitors
NCT00851721Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2009
- Primary completion
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of anti-inhibitor coagulant complex in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Takeda. Primary endpoint: Annualized Bleeding Episode Rate at 12 months. Started Mar 2009; status: completed.
02
Drugs
anti-inhibitor coagulant complex
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT00851721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851721.